Not registered yet? Please contact our project manager Dr. Mary Gazea . This area is only for members of the research consortium.


29 November 2021

Submission of first periodic report to European Commission

Today, the DECISION Consortium submitted the first periodic report to the European Commission. Over a period of more than two months all partners worked hard to report work performed, results and efforts. The PMO thanks all involved people for their great collaboration and diligent work.

More news


10 September 2021

3rd General Assembly Meeting successfully completed

During DECISION’s first ever hybrid-meeting, 34 participants gathered face-to-face from 8-10 September in sunny Castelldefels (Barcelona), Spain. Additionally, 20 participants joined us remotely via Zoom. Discussions on novel rat models and the clinical study, as well as a poster session for the Early Career Scientists, were only a few highlights. Thanks to the amazing work of all partners, the project is progressing well.

More events

Our Vision

DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well characterized patient cohorts. The ultimate goal is to significantly reduce mortality through combinatorial therapies that are tailored to the specific needs of individual patients. Part of this endeavour is to develop a reliable prognostic test and a robust response test.

Learn more

Why it matters

In 2013, cirrhosis was responsible for 1.2 million deaths worldwide. While most cirrhosis patients initially do not show symptoms, acute decompensation of cirrhosis, defined as the body’s inability to cope with the progressing dysfunctionality of the liver, leads to drastic symptoms. Decompensation is characterized by the development of ascites, hepatic encephalopathy, jaundice, or gastrointestinal haemorrhage, and is often a turning point for cirrhosis.

Learn more